As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
As per union government, growing public participation reflects rising awareness and collective commitment towards advancing organ and tissue donation
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Pharma powerhouse names Cecile Guegan interim finance chief
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Veteran health innovation and policy leader to drive biotechnology innovation, startup growth and commercialization of indigenous technologies
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Backs Lifesigns in first bet and doubles down on India’s healthcare AI surge
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
